Business Wire

Sigma Systems Advances Its Product Portfolio for the Next Generation of Digital Services and Sees Growth in Customer Adoption

Del

Sigma Systems, the global leader in catalog-driven software, today announced their latest product innovations in support of communications service providers looking to quickly adopt new business models for the next generation of digital services, while combining them with their core services. Sigma will be demonstrating these business-critical capabilities at TM Forum’s Digital Transformation World taking place May 14-16th in Nice, France.

Catherine Michel, CTO of Sigma Systems, commented: “We’re at a very exciting time in the industry. Service providers need to be able to dynamically connect and sell the incessant waves of new digital services with the persistence of legacy services, without having to manually intervene in the process. Service providers need to behave much more as lifestyle providers, recognizing that rapid innovation with mass personalization must be a business-as-usual approach to the market. Sigma has been advancing our technology for the onslaught of these living digital services – IoT, connected cars, connected homes - to help service providers create, sell and deliver new product innovations in a dynamic environment.”

The products that comprise the Sigma Create-Sell-Deliver Portfolio are Sigma Catalog, Sigma Configure Price Quote, Sigma Order Management, Sigma Provisioning, and Sigma Insights. These products are all individually deployable, or available as a pre-integrated, best-of-breed solutions. Several major service providers worldwide continue to adopt either model, most recently the global satellite provider Inmarsat, Indonesian mobile services provider Telkomsel serving 190 million subscribers, and Telstra, Australia’s largest communications services provider for consumer and enterprise markets.

A brief update of the latest product innovations from across the Sigma Create-Sell-Deliver Portfolio follows.

Sigma Catalog. Several capabilities have been added to Sigma Catalog that further enable service providers to dynamically manage the definition, bundling and launch of next generation living digital services as part of their BAU PLM process. Key enhancements have been made to the visualization and parallel release management of product/service/resource definitions for this purpose. Major advancements have also been made to the micro-services layer of Catalog Services, particularly in support of the contextual awareness and run-time rules execution during the quote, order capture, order decomposition and order fulfilment processes.

Sigma Configure Price Quote (CPQ). Sigma CPQ is now that only CPQ application that can be deployed as a single platform, yet physically service multiple sales channels across mobile, web, retail kiosk and desktop, making it the only true omni-channel CPQ platform. As part of these enhancements, Sigma has deepened its integration with Salesforce to support the Lightning UI standard and has productized its integration with eCommerce platforms in support of web shops and self-service via digital channels. Sigma CPQ’s unique ability to handle the complexity of quotes and orders across newer living digital services, traditional consumer services and advanced enterprise data services, has been further extended with features for dynamic change order creation and in-flight order amendments and cancellations.

Sigma Order Management. Several recent innovations to Sigma Order Management’s Über orchestration platform ensure that service providers can coordinate and manage the fulfilment of orders from any channel and onto any network technology – traditional core networks, SDNs, 5G networks, IoT devices, 3rd party networks – all in an automated environment. Examples of additional capabilities include enhanced dynamic MACD (move, add, change, delete) execution plans for both simple and complex orders, the ability to have multiple independent fulfilment plans execute in parallel per order, and enhanced broad scale workflow re-use for activities.

Sigma Provisioning. Sigma Provisioning continues to lead the market in zero-touch network activation across all core network technologies. Latest innovations around auto-deployment and continuous delivery frameworks as well as dynamic scaling mean automation has been extended to include real-time application management. A North American CSP recently determined that the automation of Sigma Provisioning saved close to millions of dollars in call center, truck rolls and other customer service activities while maintaining 100% uptime of Sigma Cloud over a one-year period.

Sigma Insights. The latest addition to the Sigma product portfolio, Sigma Insights is an intelligent data mining and analytics platform for understanding and responding to key business and technical performance indicators. The most recent innovations enhance the foundations for machine learning business intelligence through a new agent framework for the dynamic collection of data, a more configurable way of sharing event data with third-party applications and new querying APIs for faster data mining of Sigma Insights events.

As a cross-portfolio architecture strategy, with each software release Sigma continues to capitalize on its micro-services infrastructure, its no-code zone approach to deployment through its data-driven configuration framework, its ongoing support for the TM Forum Open Digital API initiative and its backwards compatibility software promise.

To speak with Sigma about its portfolio or to find out more about Sigma, please visit www.sigma-systems.com or email info@sigma-systems.com.

About Sigma Systems

Sigma Systems is the global leader in catalog-driven software solutions for communications, media, and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning and Insights products in addition to offering a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and Asia Pacific, with technology and integration partners globally.

Contact information

Milner Strategic Marketing Ltd.
Chloe Purcell
Strategic PR Manager
+44 1473 633123
or
Sigma Systems
Glenn Gibson
VP Marketing
+1-416-827-6851

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third